A new imaging biomarker for hypoxic tumors may open doors to new treatment pathways in oncology, according to results of a study presented at the World Molecular Imaging Congress in Nice, France, this week.
The results of the safety study indicated that HX4, a new imaging biomarker developed at Siemens Molecular Imaging Biomarker Research, is safe for use in human PET imaging studies.
Hypoxic cells are clinically problematic and tend to be less responsive to standard treatment regimens. The development of an imaging biomarker that selectively identifies hypoxic tumor cells could help radiation oncologists tailor specific treatment options to most efficiently manage disease.
The study included initial human data regarding bio-distribution of the new agent, radiation dosimetry levels in normal volunteers and optimal patient imaging parameters with PET. Results of the study indicated that the compound was found to be stable for imaging at 145 minutes post injection, that it would safely clear the body through urinary elimination and that there were very low dose accumulations in major organs.
The HX4 imaging biomarker is intended for exclusive world wide distribution by PETNET Solutions, a fully owned Siemens subsidiary, according to the company.